One limitation of the Harvard study was that patients were on semaglutide for a varied amount of time and developed NAION at various intervals from the start of the therapy, while a shorter interval of about 6 weeks should be expected for a drug-related complication
In its ubiquinol state, it provides a vital line of antioxidant defense
Adherence is significantly lower among those using GLP-1s for weight loss versus those using them to manage type 2 diabetes one study found that about 65% of patients without type 2 diabetes discontinued GLP-1 therapy within one year, compared to 47% of patients with type 2 diabetes
Prospective studies integrating body composition trajectories, structured dietary assessment, and redox-relevant biomarkers during GLP-1RA therapy may clarify whether preservation of rate-limiting substrate modules supports lean mass maintenance and metabolic stability
If nausea is severe or persistent, speak to your prescriber, as they may recommend delaying your dose escalation